Centocor
Executive Summary
Former SmithKline VP James Geddes joins monoclonal antibody firm as VP-sales & marketing, therapeutic products. His initial activities at Centocor will focus on prelaunch and launch activities for Centoxin, a product for treatment of septic shock. He is also charged with establishing a U.S.-based therapeutic sales force. Geddes joined SmithKline in 1968 and most recently directed the company's government, customer relations and national accounts programs as a VP in the U.S. Pharmaceuticals Marketing Division of Smith Kline & French.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.